Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望

智通财经2025-07-31

智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面"不劣于"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

稳稳稳稳稳
2025-07-31
稳稳稳稳稳
胡说八道呀

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555388898?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-31 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555388898","market":"us","top_or_hot":-1,"title":"Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1324416.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-31 20:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1324416.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1324416.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.USD","symbol_name":"United Global Healthcare Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1324416.html","article_id":"2555388898","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555388898","pubTimestamp":1753963243,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。与Trulicity组相比，该药物使用者的全因死亡率低16%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LLY":"礼来","SG9999014906.USD":"大华全球优质成长基金Acc USD","BK4599":"减肥药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4585":"ETF&股票定投概念","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC"},"translate_title":"Mounjaro's cardiovascular protection effect does not surpass Trulicity! Eli Lilly (LLY.US) Disappoints Markets","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这一目标，但研究结果打破了投资者对Mounjaro显著优于老药的期待。分析师迈克尔·沙阿表示，\"完全没有提及优效性——而礼来也确实进行了这项测试，\"\"因此市场反应可能会很消极。\"礼来的股价在纽约盘前交易中一度下跌5.3%，截至发稿，其跌幅收窄至1%。这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。Mounjaro在其他健康指标上表现更佳。与Trulicity组相比，该药物使用者的全因死亡率低16%。礼来表示，Mounjaro组患者在血糖控制、减重和降压方面改善更明显。两种药物最常见的不良反应均为轻度胃肠道症状。Mounjaro使用者减重更多但心血管风险降幅相当的现象表明，这类被称为GLP-1的药物可能具有独立于减重效果的心脏保护作用。礼来将于9月在医学会议上公布完整研究，并计划年底前向全球药监机构提交新数据，以寻求将降低心血管风险纳入Mounjaro的适应症。礼来心血管代谢业务总裁肯·卡斯特在声明中表示，\"这些发现强化了Mounjaro作为2型糖尿病合并心血管疾病患者一线治疗选择的潜力。\"Trulicity早在2020年就获得美国监管部门批准用于降低2型糖尿病患者主要心血管事件风险。礼来与竞争对手诺和诺德正竞相拓展旗下药物在糖尿病和减肥之外的适应症研究。虽然多数保险公司承保糖尿病治疗，但许多机构不愿覆盖减肥用途。诺和诺德已证实Ozempic和Wegovy均可降低肥胖和糖尿病患者的心血管事件风险，相关适应症标签使其在与保险机构和政府医保谈判中占据优势。不过，即便未获批心血管适应症，礼来仍从诺和诺德手中夺取了可观市场份额。该公司并未专门针对减肥药Zepbound开展心血管风险研究，而是通过一项长达数年的大型试验评估其降低全因死亡率的效果，最终数据预计要到2027年才能出炉。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":462688874021192,"gmtCreate":1753967014770,"gmtModify":1753967016408,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"htmlText":"胡说八道呀","listText":"胡说八道呀","text":"胡说八道呀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/462688874021192","repostId":2555388898,"repostType":2,"repost":{"id":"2555388898","kind":"news","pubTimestamp":1753963243,"share":"https://www.laohu8.com/m/news/2555388898?lang=zh_CN&edition=full","pubTime":"2025-07-31 20:00","market":"us","language":"zh","title":"Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望","url":"https://stock-news.laohu8.com/highlight/detail?id=2555388898","media":"智通财经","summary":"这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。与Trulicity组相比，该药物使用者的全因死亡率低16%。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。</p><p>这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。</p><p>虽然达到了这一目标，但研究结果打破了投资者对Mounjaro显著优于老药的期待。</p><p>分析师迈克尔·沙阿表示，<span>\"完全没有提及优效性——而礼来也确实进行了这项测试，\"</span>\"因此市场反应可能会很消极。\"</p><p>礼来的股价在纽约盘前交易中一度下跌5.3%，截至发稿，其跌幅收窄至1%。</p><p>这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药<span>Trulicity</span>。</p><p>Mounjaro在其他健康指标上表现更佳。与Trulicity组相比，该药物使用者的全因死亡率低16%。礼来表示，Mounjaro组患者在血糖控制、减重和降压方面改善更明显。两种药物最常见的不良反应均为轻度胃肠道症状。</p><p>Mounjaro使用者减重更多但心血管风险降幅相当的现象表明，这类被称为GLP-1的药物可能具有独立于减重效果的心脏保护作用。礼来将于9月在医学会议上公布完整研究，并计划年底前向全球药监机构提交新数据，以寻求将降低心血管风险纳入Mounjaro的适应症。</p><p>礼来心血管代谢业务总裁肯·卡斯特在声明中表示，<span>\"这些发现强化了Mounjaro作为2型糖尿病合并心血管疾病患者一线治疗选择的潜力。\"</span></p><p>Trulicity早在2020年就获得美国监管部门批准用于降低2型糖尿病患者主要心血管事件风险。</p><p>礼来与竞争对手<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>正竞相拓展旗下药物在糖尿病和减肥之外的适应症研究。虽然多数保险公司承保糖尿病治疗，但许多机构不愿覆盖减肥用途。诺和诺德已证实Ozempic和Wegovy均可降低肥胖和糖尿病患者的心血管事件风险，相关适应症标签使其在与保险机构和政府医保谈判中占据优势。</p><p>不过，即便未获批心血管适应症，礼来仍从诺和诺德手中夺取了可观市场份额。该公司并未专门针对减肥药Zepbound开展心血管风险研究，而是通过一项长达数年的大型试验评估其降低全因死亡率的效果，最终数据预计要到2027年才能出炉。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-31 20:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1324416.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1324416.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LLY":"礼来","SG9999014906.USD":"大华全球优质成长基金Acc USD","BK4599":"减肥药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4585":"ETF&股票定投概念","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1324416.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2555388898","content_text":"智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这一目标，但研究结果打破了投资者对Mounjaro显著优于老药的期待。分析师迈克尔·沙阿表示，\"完全没有提及优效性——而礼来也确实进行了这项测试，\"\"因此市场反应可能会很消极。\"礼来的股价在纽约盘前交易中一度下跌5.3%，截至发稿，其跌幅收窄至1%。这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。Mounjaro在其他健康指标上表现更佳。与Trulicity组相比，该药物使用者的全因死亡率低16%。礼来表示，Mounjaro组患者在血糖控制、减重和降压方面改善更明显。两种药物最常见的不良反应均为轻度胃肠道症状。Mounjaro使用者减重更多但心血管风险降幅相当的现象表明，这类被称为GLP-1的药物可能具有独立于减重效果的心脏保护作用。礼来将于9月在医学会议上公布完整研究，并计划年底前向全球药监机构提交新数据，以寻求将降低心血管风险纳入Mounjaro的适应症。礼来心血管代谢业务总裁肯·卡斯特在声明中表示，\"这些发现强化了Mounjaro作为2型糖尿病合并心血管疾病患者一线治疗选择的潜力。\"Trulicity早在2020年就获得美国监管部门批准用于降低2型糖尿病患者主要心血管事件风险。礼来与竞争对手诺和诺德正竞相拓展旗下药物在糖尿病和减肥之外的适应症研究。虽然多数保险公司承保糖尿病治疗，但许多机构不愿覆盖减肥用途。诺和诺德已证实Ozempic和Wegovy均可降低肥胖和糖尿病患者的心血管事件风险，相关适应症标签使其在与保险机构和政府医保谈判中占据优势。不过，即便未获批心血管适应症，礼来仍从诺和诺德手中夺取了可观市场份额。该公司并未专门针对减肥药Zepbound开展心血管风险研究，而是通过一项长达数年的大型试验评估其降低全因死亡率的效果，最终数据预计要到2027年才能出炉。","news_type":1,"symbols_score_info":{"LLY":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555388898","isCrawlerRequest":true}